The tyrosine kinase inhibitor lenvatinib demonstrated promising activity and safety in patients with advanced hepatocellular carcinoma in a retrospective multicenter observational analysis in Korea, according to a poster presentation at the 2020 Gastrointestinal Cancers Symposium.
The tyrosine kinase inhibitor lenvatinib (Lenvima) demonstrated promising activity and safety in patients with advanced hepatocellular carcinoma (HCC) in a retrospective multicenter observational analysis in Korea, according to a poster presentation at the 2020 Gastrointestinal (GI) Cancers Symposium.
The overall response rate (ORR) in the total population (n = 75), as assessed per RECIST version 1.1 was 10.7%. In the cohort of patients that received lenvatinib in the frontline setting (n = 50), the ORR was 14.0% versus 4.0% in those that received therapy in the second- to fourth-line settings (n = 25). The disease control rate (DCR) was 77.4% overall compared with 78.0% in the frontline and 76.0% in the later lines.
A complete response (CR) was not observed in any patients, but 8 patients in the overall population had a partial response (PR). Seven patients and 1 patient had a PR in the first- and later-line cohorts, respectively. Stable disease (SD) was observed in 50 patients overall (66.7%), including 32 patients in the frontline cohort (64.0%) and 18 patients in the later-line cohort (72.0%). Progressive disease (PD) was noted in 17 patients overall (22.7%) versus 11 patients treated in the frontline (22.0%) and 6 patients in later lines (24.0%).
In the overall patient population at a median follow-up of 4.7 months, the median overall survival (OS) was 6.7 months (95% CI, 5.2-8.1), and the median progression-free survival (PFS) was 4.6 months (95% CI, 3.6-5.6). In the frontline cohort, the median OS was 6.7 months (95% CI, 4.7-8.7), and the median PFS was 4.6 months (95% CI, 3.0-6.2) compared with 6.4 months (95% CI, 4.9-7.8) and 4.4 months (95% CI, 3.2-5.6) in the later line cohort, respectively.
Survival outcomes were also stratified by Child-Pugh class. In the patients with Child-Pugh A status (n = 57), the median OS was 7.1 months (95% CI, 5.7-8.5), and the median PFS was 4.6 months (95% CI, 3.5-5.7). In the 18 patients with Child-Pugh B status, the median OS was 5.3 months (95% CI, 2.0-8.5), and the median PFS was 2.6 months (95% CI, 0.6-4.6).
Investigators also analyzed the efficacy in patients who would have beenexcluded fromthe pivotal phase III REFLECT trial, such as those with tumor burdens occupying 50% or more of the liver, bile duct invasion, main portal vein invasion, and decreased liver function (Child-Pugh B and C). In these patients (n = 46), the ORR was 4.3% with RECIST 1.1 criteria. Two patients achieved a PR (4.3%), 33 had SD (71.7%), and 11 had PD (23.9%). The DCR was 76.0%.
In the cohort of patients who received prior immune checkpoint inhibitors (n = 13), 10 patients had SD (76.9%) and 3 had PD (23.1%). However, no patients had an objective response. The DCR was 76.9%.
Efficacy was also analyzed using modified RECIST criteria, which demonstrated similar results. The ORR in the total population was 12.0% versus 16.0% and 4.0% in those that received therapy in the first- and later-lines, respectively. In the group of patients who did not meet the inclusion criteria for REFLECT, the ORR was 8.7%.
Adverse events (AEs) of any grade were observed in 60 patients (80.0%), and the most common included aspartate aminotransferase (AST) elevation (61.3%), fatigue (37.3%), alanine aminotransferase elevation (29.3%), hyperbilirubinemia (29.3%), and thrombocytopenia (28.0%). Overall, 23 patients experienced grade 3/4 AEs (30.7%). Grade 3/4 events included hyperbilirubinemia (10.7%); AST elevation (8.0%); diarrhea (5.3%); hypertension (4.0%); thrombocytopenia (2.7%); and nausea, neutropenia, and proteinuria in 1 patient each (1.3%). Overall, 18 patients required a dose interruption or reduction due to AEs (24.0%).
To be included in the study, patients had to have a histologically or radiographically confirmed diagnosis of HCC, Child-Pugh class A or B, Barcelona clinic liver cancer (BCLC) B or C stage, and have at least 1 follow-up visit after initiation of lenvatinib therapy. Patients who were treated with lenvatinib between September 2018 and November 2019 from 3 Korean institutions were included in the analysis (n = 75).
Overall, 56 patients were male (74.7%) and 42 patients had an ECOG status of 0 or 1 (56.0%). Fifty-seven patients had Child-Pugh class A (76.0%) versus 18 patients with class B (24.0%). The majority of patients were BCLC stage C (66; 88.0%) compared with 9 patients in stage B (12.0%). The lenvatinib therapy was used in the frontline setting for 50 patients (66.7%), in the second-line setting for 14 patients (18.7%), and in the third-line or beyond in 11 patients (14.6%). Twenty-five patients had a prior systemic therapy (33.3%), and 23 patients had undergone surgery prior to treatment (30.7%).
Reference:
Cheon J, Yoo C, Bang J, et al. The efficacy and safety of lenvatinib (LEN) in Korean patients (pts) with advanced hepatocellular carcinoma (aHCC); multicenter retrospective analysis.J Clin Oncol. 2020;38(suppl 15;abstr 490).
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More